2-[(5-bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)thiophene | CAS:1030825-20-7

We serve 2-[(5-bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)thiophene CAS:1030825-20-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-[(5-bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)thiophene

Chemical Name:2-[(5-bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)thiophene
CAS.NO:1030825-20-7
Synonyms:2-(5-Bromo-2-methylbenzyl)-5-(4-fluorophenyl)thiophene
Molecular Formula:C18H14BrFS
Molecular Weight:361.27100
 
Specification:
Appearance:Off-white powder
Purity:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Canagliflozin
 
Note:The product under valid patents will not be offered to the countries covered by patents.



Contact us for information like 2-[(5-bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)thiophene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(5-Bromo-2-methylbenzyl)-5-(4-fluorophenyl)thiophene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-[(5-bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)thiophene Use and application,2-[(5-bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)thiophene technical grade,usp/ep/jp grade.


Related News: Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.Difluoromethylthioacetic acid manufacturer Social media users — including numerous medical experts — questioned whether the findings were supported by clinical evidence from treating coronavirus patients.D-Glutamine supplier The downstream industry of the pharmaceutical intermediate industry is mainly the production of APIs, and the relationship between APIs and preparations is in the upstream and downstream industry chain. The consumer demand for downstream preparations will directly affect the demand for APIs.Methyl 2-cyanoisonicotinate vendor Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).